{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:24:40Z","timestamp":1778135080597,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,10,30]],"date-time":"2011-10-30T00:00:00Z","timestamp":1319932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s12032-011-0092-9","type":"journal-article","created":{"date-parts":[[2011,10,29]],"date-time":"2011-10-29T06:53:58Z","timestamp":1319871238000},"page":"2136-2142","source":"Crossref","is-referenced-by-count":7,"title":["Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia"],"prefix":"10.1007","volume":"29","author":[{"given":"N\u00f3ra","family":"Meggyesi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"Kalm\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1ndor","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Tordai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajnalka","family":"Andrikovics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,30]]},"reference":[{"issue":"23","key":"92_CR1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"24","key":"92_CR2","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009;15(24):7519\u201327.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"92_CR3","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.leukres.2007.04.018","volume":"32","author":"RP Curvo","year":"2008","unstructured":"Curvo RP, Zalcberg IR, Scholl V, Pires V, Moellmann-Coelho A, Moreira MA. A recurrent splicing variant without c-ABL Exon 7 in imatinib-resistant patients. Leuk Res. 2008;32(3):508\u201310.","journal-title":"Leuk Res"},{"issue":"11","key":"92_CR4","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.leu.2404400","volume":"20","author":"FX Gruber","year":"2006","unstructured":"Gruber FX, Hjorth-Hansen H, Mikkola I, Stenke L, Johansen T. A novel Bcr-Abl splice isoform is associated with the L248\u00a0V mutation in CML patients with acquired resistance to imatinib. Leukemia. 2006;20(11):2057\u201360. doi: 10.1038\/sj.leu.2404400 .","journal-title":"Leukemia"},{"issue":"3","key":"92_CR5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1751-553X.2010.01291.x","volume":"33","author":"W Ma","year":"2011","unstructured":"Ma W, Giles F, Zhang X, Wang X, Zhang Z, Lee TS, et al. Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors. Int J Lab Hematol. 2011;33(3):326\u201331. doi: 10.1111\/j.1751-553X.2010.01291.x .","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"92_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000210060","volume":"121","author":"W Ma","year":"2009","unstructured":"Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009;121(1):27\u201331.","journal-title":"Acta Haematol"},{"issue":"12","key":"92_CR7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/ng.259","volume":"40","author":"Q Pan","year":"2008","unstructured":"Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40(12):1413\u20135. doi: 10.1038\/ng.259 .","journal-title":"Nat Genet"},{"issue":"7221","key":"92_CR8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nature07509","volume":"456","author":"ET Wang","year":"2008","unstructured":"Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature. 2008;456(7221):470\u20136. doi: 10.1038\/nature07509 .","journal-title":"Nature"},{"issue":"1","key":"92_CR9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1073\/pnas.0136770100","volume":"100","author":"BP Lewis","year":"2003","unstructured":"Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA. 2003;100(1):189\u201392. doi: 10.1073\/pnas.01367701000136770100 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"92_CR10","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1089\/ars.2007.1817","volume":"9","author":"MM Kincaid","year":"2007","unstructured":"Kincaid MM, Cooper AA. ERADicate ER stress or die trying. Antioxid Redox Signal. 2007;9(12):2373\u201387. doi: 10.1089\/ars.2007.1817 .","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"92_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1083\/jcb.200309132","volume":"165","author":"S Vashist","year":"2004","unstructured":"Vashist S, Ng DT. Misfolded proteins are sorted by a sequential checkpoint mechanism of ER quality control. J Cell Biol. 2004;165(1):41\u201352. doi: 10.1083\/jcb.200309132 .","journal-title":"J Cell Biol"},{"issue":"2","key":"92_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2353\/jmoldx.2008.070128","volume":"10","author":"J Laudadio","year":"2008","unstructured":"Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn. 2008;10(2):177\u201380. doi: 10.2353\/jmoldx.2008.070128 .","journal-title":"J Mol Diagn"},{"issue":"6","key":"92_CR13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/leu.2008.65","volume":"22","author":"DW Sherbenou","year":"2008","unstructured":"Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008;22(6):1184\u201390.","journal-title":"Leukemia"},{"issue":"12","key":"92_CR14","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1535-7163.MCT-08-0482","volume":"7","author":"TS Lee","year":"2008","unstructured":"Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, et al. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008;7(12):3834\u201341.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"92_CR15","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1158\/1535-7163.MCT-10-0595","volume":"9","author":"JB Gaillard","year":"2011","unstructured":"Gaillard JB, Arnould C, Bravo S, Donadio D, Exbrayat C, Jourdan E, et al. Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. Mol Cancer Ther. 2011;9(11):3083\u20139. doi: 10.1158\/1535-7163.MCT-10-0595 .","journal-title":"Mol Cancer Ther"},{"issue":"35","key":"92_CR16","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041\u201351.","journal-title":"J Clin Oncol"},{"issue":"12","key":"92_CR17","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","volume":"13","author":"JJ Dongen van","year":"1999","unstructured":"van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901\u201328.","journal-title":"Leukemia"},{"issue":"9","key":"92_CR18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","volume":"93","author":"T Ernst","year":"2008","unstructured":"Ernst T, Hoffmann J, Erben P, Hanfstein B, Leitner A, Hehlmann R, et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2008;93(9):1389\u201393.","journal-title":"Haematologica"},{"issue":"12","key":"92_CR19","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/bip.360221211","volume":"22","author":"W Kabsch","year":"1983","unstructured":"Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983;22(12):2577\u2013637. doi: 10.1002\/bip.360221211 .","journal-title":"Biopolymers"},{"issue":"13","key":"92_CR20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605\u201312. doi: 10.1002\/jcc.20084 .","journal-title":"J Comput Chem"},{"issue":"3","key":"92_CR21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q","volume":"40","author":"JA Cuff","year":"2000","unstructured":"Cuff JA, Barton GJ. Application of multiple sequence alignment profiles to improve protein secondary structure prediction. Proteins. 2000;40(3):502\u201311. doi: 10.1002\/1097-0134(20000815)40:3<502:AID-PROT170>3.0.CO;2-Q .","journal-title":"Proteins"},{"issue":"6","key":"92_CR22","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1110\/ps.9.6.1162","volume":"9","author":"M Ouali","year":"2000","unstructured":"Ouali M, King RD. Cascaded multiple classifiers for secondary structure prediction. Protein Sci. 2000;9(6):1162\u201376. doi: 10.1110\/ps.9.6.1162 .","journal-title":"Protein Sci"},{"issue":"1","key":"92_CR23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1110\/ps.041047005","volume":"14","author":"PJ Fleming","year":"2005","unstructured":"Fleming PJ, Fitzkee NC, Mezei M, Srinivasan R, Rose GD. A novel method reveals that solvent water favors polyproline II over beta-strand conformation in peptides and unfolded proteins: conditional hydrophobic accessible surface area (CHASA). Protein Sci. 2005;14(1):111\u20138. doi: 10.1110\/ps.041047005 .","journal-title":"Protein Sci"},{"issue":"4","key":"92_CR24","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/nar\/gkq843","volume":"39","author":"H Hegyi","year":"2011","unstructured":"Hegyi H, Kalmar L, Horvath T, Tompa P. Verification of alternative splicing variants based on domain integrity, truncation length and intrinsic protein disorder. Nucleic Acids Res. 2011;39(4):1208\u201319. doi: 10.1093\/nar\/gkq843 .","journal-title":"Nucleic Acids Res"},{"issue":"5486","key":"92_CR25","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289(5486):1938\u201342.","journal-title":"Science"},{"issue":"3","key":"92_CR26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.leukres.2008.08.024","volume":"33","author":"EH Cho","year":"2009","unstructured":"Cho EH, Kang SK, Kim SY. Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on \u201cA recurrent splicing variant without c-ABL Exon 7 in imatinib-resistant patients\u201d by Curvo et al. [Leuk. Res.]. Leuk Res. 2009;33(3):505\u20136.","journal-title":"Leuk Res"},{"issue":"7","key":"92_CR27","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/1535-7163.MCT-10-0311","volume":"9","author":"JS Khorashad","year":"2010","unstructured":"Khorashad JS, Milojkovic D, Reid AG. Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue\u2014letter. Mol Cancer Ther. 2010;9(7):2152.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"92_CR28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1158\/1535-7163.MCT-09-0078","volume":"9","author":"I Santamaria","year":"2010","unstructured":"Santamaria I, Pitiot AS, Balbin M. ABL alternative splicing is quite frequent in normal population\u2014letter. Mol Cancer Ther. 2010;9(3):772. author reply.","journal-title":"Mol Cancer Ther"},{"key":"92_CR29","doi-asserted-by":"crossref","unstructured":"Gruber FX, Lundan T, Goll R, Silye A, Mikkola I, Rekvig OP et al. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations? Med Oncol. 2011. doi: 10.1007\/s12032-010-9781-z .","DOI":"10.1007\/s12032-010-9781-z"},{"issue":"3","key":"92_CR30","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.cell.2010.07.022","volume":"142","author":"LE Maquat","year":"2010","unstructured":"Maquat LE, Tarn WY, Isken O. The pioneer round of translation: features and functions. Cell. 2010;142(3):368\u201374. doi: 10.1016\/j.cell.2010.07.022 .","journal-title":"Cell"},{"issue":"28","key":"92_CR31","doi-asserted-by":"crossref","first-page":"11572","DOI":"10.1073\/pnas.1104104108","volume":"108","author":"S Apcher","year":"2011","unstructured":"Apcher S, Daskalogianni C, Lejeune F, Manoury B, Imhoos G, Heslop L, et al. Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc Natl Acad Sci USA. 2011;108(28):11572\u20137. doi: 10.1073\/pnas.1104104108 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"92_CR32","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/bioinformatics\/btr198","volume":"27","author":"M Floris","year":"2011","unstructured":"Floris M, Raimondo D, Leoni G, Orsini M, Marcatili P, Tramontano A. MAISTAS: a tool for automatic structural evaluation of alternative splicing products. Bioinformatics. 2011;27(12):1625\u20139. doi: 10.1093\/bioinformatics\/btr198 .","journal-title":"Bioinformatics"},{"issue":"Pt 1","key":"92_CR33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","volume":"63","author":"SW Cowan-Jacob","year":"2007","unstructured":"Cowan-Jacob SW, Fendrich G, Floersheimer A, Furet P, Liebetanz J, Rummel G, et al. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr. 2007;63(Pt 1):80\u201393. doi: 10.1107\/S0907444906047287 .","journal-title":"Acta Crystallogr D Biol Crystallogr"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0092-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-0092-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-0092-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:54Z","timestamp":1559442174000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-0092-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,30]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-0092-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,30]]}}}